Abstract
Background: Previous studies identified patient selection criteria for therapy success in Upper Airway Stimulation (Inspire Medical Systems, USA) for treatment of moderate-to-severe OSA in patients intolerant to continuous positive airway pressure. The current study reported therapy response at 12-months post-implant in subjects who met selection criteria.
Methods: Among 34 implanted subjects, 18 met criteria for responder and 16 did not. AHI (Level 1 monitoring) were measured at 12 months. All patients were monitored for device-related adverse events and patients met selection criteria were examined for therapy response during over-night PSG.
Results: There were no device malfunctions or un-anticipated device-related adverse events from 6-12 months. Among patients who met selection criteria and for which data are available, the AHI reduction was maintained at 12-month. Improvement for ESS and FOSQ were also observed in these subjects from baseline to 6-month, 10.7 ± 5.4 to 7.5 ± 4.1 (p=0.03), and 88.8 ± 22.1 to 104.6 ± 13.7 (p=0.01) for ESS and FOSQ, respectively. AHI remained unchanged at 12-month for patients that did not meet selection criteria.
Conclusion: The current study has demonstrated that Upper Airway Stimulation to treat OSA has a sustained therapy efficacy at 12-month post-implant in a selected group of moderate-to-severe OSA subjects.
- © 2012 ERS